Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Interleukin-6 inhibitors in the treatment of rheumatoid arthritis

Authors Hennigan S, Kavanaugh A

Published 8 August 2008 Volume 2008:4(4) Pages 767—775

DOI https://doi.org/10.2147/TCRM.S3470

Review by Single-blind

Peer reviewer comments 4

Stephanie Hennigan, Arthur Kavanaugh

Division of Rheumatology, Allergy, Immunology, The University of California, San Diego, CA, USA

Abstract: Recent developments in understanding the immunopathogenesis of rheumatoid arthritis (RA), combined with progress in biopharmaceutical development, have facilitated the introduction of novel immune modulating therapies for this progressive debilitating disorder. Efficacy achieved with certain agents, particularly the TNF inhibitors, has spurred the development of additional biologic agents targeting other components of the dysregulated immune response relevant to the etiology and sustenance of immune driven systemic inflammation characteristic of RA. Among these other potential targets is IL-6, a cytokine with effects on numerous cell types, including those involved in the pathogenesis of RA. Based on its activities, IL-6 appeared to be a viable target for autoimmune disease. Inhibitors of IL-6 were successful in animal models of autoimmune disease paving the way for subsequent studies in humans. The greatest experience to date has been with tocilizumab, a humanized monoclonal antibody specific for the IL-6 receptor (IL-6R). Beginning with open label studies, and progressing through larger and more rigorous controlled trials, tocilizumab has been shown to have significant efficacy in patients with RA. Additional studies analyzing its effects in varied populations of RA patients, as well as greater detail concerning its longer-term tolerability and safety, will help define the ultimate role of tocilizumab and other future inhibitors of IL-6 activity as potential therapies for RA.

Keywords: rheumatoid arthritis, IL-6, tocilizumab, biologic agents

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy

Stephanie Hennigan, Christoph Ackermann, Arthur Kavanaugh

Core Evidence 2007, 2:0-0

Published Date: 15 December 2007

Readers of this article also read:

Nursing faculty teaching a module in clinical skills to medical students: a Lebanese experience

Abdallah B, Irani J, Sailian SD, Gebran VG, Rizk U

Advances in Medical Education and Practice 2014, 5:427-432

Published Date: 13 November 2014

Serum lipid profile and correlates in newly presenting Nigerians with arterial hypertension

Adamu UG, Okuku GA, Oladele CO, Abdullahi A, Oduh JI, Fasae AJ

Vascular Health and Risk Management 2013, 9:763-768

Published Date: 3 December 2013

Omalizumab: the evidence for its place in the treatment of allergic asthma

Diarmuid M. McNicholl, Liam G. Heaney

Core Evidence 2008, 3:0-0

Published Date: 31 December 2008

Risk stratification for arrhythmic death in an emergency department cohort: a new method of nonlinear PD2i analysis of the ECG

James E Skinner, Michael Meyer, William C Dalsey, Brian A Nester, George Ramalanjaona, et al

Therapeutics and Clinical Risk Management 2008, 4:689-697

Published Date: 8 August 2008

Relative safety profiles of high dose statin regimens

Carlos Escobar, Rocio Echarri, Vivencio Barrios

Vascular Health and Risk Management 2008, 4:525-533

Published Date: 6 June 2008

Lapatinib: the evidence for its therapeutic value in metastatic breast cancer

Andrew Thomson

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction

Carole Nadin

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005